Work

Pre-clinical evaluation of a divalent liposomal vaccine to control invasive candidiasis

Year: 2025

Type: article

Abstract: Candida albicans causes systemic infections with 20-50% mortality in critically ill and immunocompromised patients, despite antifungal treatment. Current therapies face limitations, including toxicity and resistance, underscoring the need for prophylactic vaccines. This study presents a novel divalent liposomal vaccine, delivering C. albicans Cht3 and Sap2 antigens. Vaccination induced protective Th1/Th17 immunity, a balanced Th1/Th2 ratio, antigen-specific antibodies, and boosted macrophage activity, improving survival in a mouse model of invasive candidiasis.

Source: npj Vaccines

DOI: 10.1038/s41541-025-01183-0

Authors: Augusto Costa-Barbosa, Maria Inês Pacheco, Andreia C. Gomes, Tony Collins, Manuel Vilanova, Célia Pais, Alexandra Correia, Paula Sampaio

Institutions: Centro de Biologia Molecular e Ambiental, Instituto de Ciência e Inovação para a Bio-Sustentabilidade, University of Minho, Universidade do Porto, i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Instituto de Biologia Molecular e Celular

Language: English

Topic: Antifungal resistance and susceptibility

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,890

Funder: Fundação para a Ciência e a Tecnologia

Awards: CENTRO DE BIOLOGIA MOLECULAR E AMBIENTAL, Rede de Infraestruturas em Investigação Aquática, Development of a new antifungal strategy based on lipid-encapsulated benzo(a) phenoxazine derivatives, G5454278309, New generation antigen delivery system for Candida albicans recombinant proteins as a vaccination strategy against systemic fungal infections, New generation antigen delivery system for Candida albicans recombinant proteins as a vaccination strategy against systemic fungal infections

OpenAlex ID: W4411285310

FWCI: 5.856

Cites: 23

Cited by: 8

Related to: 10